CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Bio-Rad's Q3 revenue comes slightly above estimates on Clinical Diagnostics growth

By Reuters News


Overview

  • Life science and diagnostics provider's Q3 revenue rose 0.5% yr/yr, led by Clinical Diagnostics

  • Adjusted EPS for Q3 increased to $2.65 from $2.26 a year earlier

  • Net income swung to a profit, driven by gain on Sartorius AG investment


Outlook

  • Bio-Rad expects 2026 non-GAAP, currency-neutral revenue to range from down 3% to up 0.5%

  • Company maintains 2026 non-GAAP operating margin outlook at 10% to 12%


Result Drivers

  • CLINICAL DIAGNOSTICS GROWTH - Higher sales in Clinical Diagnostics segment, particularly in quality systems and diabetes products, drove overall revenue growth

  • DROPLET DIGITAL PCR DEMAND - Increased demand for Droplet Digital PCR instruments partially offset declines in Life Science segment sales

  • PROCESS CHROMATOGRAPHY WEAKNESS - Lower process chromatography sales and challenges in the academic research market weighed on Life Science segment revenue


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$656.40 mln

$649.95 mln (2 Analysts)

Q3 EPS

$17.02

Q3 Net Income

$458.60 mln

Q3 Gross Margin

50.10%

Q3 EBIT Margin

-7.60%

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

  • Wall Street's median 12-month price target for Bio-Rad Laboratories, Inc. is $362.50, about 3.3% below its November 3 closing price of $374.91

  • The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 35 three months ago


Reuters Recommended Reads

  • Nov 3 - Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

  • Nov 4 - Bruker Q3 revenue tops estimates on US academic unit strength

  • Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.